$1.72
0.16.17%
Last update: Nov 5, 3:17 AM
enGene Therapeutics Inc
ENGNNASDAQ
The average analyst price target for enGene Therapeutics is $18.04, 936.8% above the current price. Of 11 analysts, 6 rate it Buy, 4 Hold and 1 Sell. Targets range from $2 to $34. The latest change came on Jun 18, 2026, when Morgan Stanley downgraded enGene Therapeutics from Equal-Weight to Underweight.
Price Target Range — 11 Quarters
Analyst Consensus — 11 Analysts
Rating Trend — Last 9 Months
